Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Free Report) in a report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of Bellerophon Therapeutics stock opened at $0.04 on Friday. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.42. The stock has a market cap of $440,388.00, a price-to-earnings ratio of -0.04 and a beta of 0.70. The company has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.05.

About Bellerophon Therapeutics

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Further Reading

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.